Portal de Periódicos da CAPES

Triple Therapy for Hepatitis C Virus Infection in Patients Receiving Hemodialysis

2014; American College of Physicians; Volume: 160; Issue: 8 Linguagem: Inglês

10.7326/l14-5008-3

1539-3704

Sara Lemoinne, Benoı̂t Barrou, Dominique Thabut,

Liver Disease Diagnosis and Treatment

Letters15 April 2014Triple Therapy for Hepatitis C Virus Infection in Patients Receiving HemodialysisSara Lemoinne, MD, Benoit Barrou, MD, and Dominique Thabut, MDSara Lemoinne, MDFrom Université Pierre et Marie Curie, Paris, France.Search for more papers by this author, Benoit Barrou, MDFrom Université Pierre et Marie Curie, Paris, France.Search for more papers by this author, and Dominique Thabut, MDFrom Université Pierre et Marie Curie, Paris, France.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5008-3 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITORWe read Liu and colleagues’ article (1) with great interest. Cure of hepatitis C virus (HCV) infection is crucial in patients receiving hemodialysis who are awaiting a kidney transplant. Hepatitis C virus infection is associated with decreased survival before and after kidney transplantation (2). However, interferon treatment after transplantation is contraindicated because of a high risk for acute rejection.Liu and colleagues report results of a randomized trial comparing the efficacy and safety of pegylated interferon plus low-dose ribavirin with those of pegylated interferon monotherapy in 205 treatment-naive patients with HCV infection receiving hemodialysis. They concluded that ...References1. Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med. 2013;159:729-38. [PMID: 24297189] LinkGoogle Scholar2. Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90:1165-71. [PMID: 20861806] CrossrefMedlineGoogle Scholar3. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-17. [PMID: 21449784] CrossrefMedlineGoogle Scholar4. Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O’Mara E, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012;51:619-28. [PMID: 22799589] CrossrefMedlineGoogle Scholar5. Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol. 2013;56:146-9. [PMID: 23149155] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Université Pierre et Marie Curie, Paris, France.Disclosures: None. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L14-0016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPegylated Interferon-α2a With or Without Low-Dose Ribavirin for Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Receiving Hemodialysis Chen-Hua Liu , Chung-Feng Huang , Chun-Jen Liu , Chia-Yen Dai , Cheng-Chao Liang , Jee-Fu Huang , Peir-Haur Hung , Hung-Bin Tsai , Meng-Kun Tsai , Shih-I Chen , Jou-Wei Lin , Sheng-Shun Yang , Tung-Hung Su , Hung-Chih Yang , Pei-Jer Chen , Ding-Shinn Chen , Wan-Long Chuang , Ming-Lung Yu , and Jia-Horng Kao Triple Therapy for Hepatitis C Virus Infection in Patients Receiving Hemodialysis Chen-Hua Liu and Jia-Horng Kao Triple Therapy for Hepatitis C Virus Infection in Patients Receiving Hemodialysis Chen-Hua Liu and Jia-Horng Kao Metrics Cited ByEpidemiology update for hepatitis C virus and hepatitis B virus in end-stage renal disease in FranceSofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center ExperienceSofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min 15 April 2014Volume 160, Issue 8Page: 581KeywordsHepatitis C virusInfectious hepatitisInterferonsLiver fibrosisProtease inhibitorsRenal failureRenal transplantationSafetyTransplantationViral load ePublished: 15 April 2014 Issue Published: 15 April 2014 CopyrightCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...